Metvixia is a drug owned by Galderma Laboratories Lp. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 08, 2016. Details of Metvixia's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6034267 | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
Mar, 2016
(8 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Metvixia is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Metvixia's family patents as well as insights into ongoing legal events on those patents.
Metvixia's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Metvixia's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 08, 2016 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Metvixia Generics:
There are no approved generic versions for Metvixia as of now.
Alternative Brands for Metvixia
Metvixia which is used for treating actinic keratoses using photodynamic therapy., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Biofrontera |
| |||
About Metvixia
Metvixia is a drug owned by Galderma Laboratories Lp. It is used for treating actinic keratoses using photodynamic therapy. Metvixia uses Methyl Aminolevulinate Hydrochloride as an active ingredient. Metvixia was launched by Galderma Labs Lp in 2004.
Approval Date:
Metvixia was approved by FDA for market use on 27 July, 2004.
Active Ingredient:
Metvixia uses Methyl Aminolevulinate Hydrochloride as the active ingredient. Check out other Drugs and Companies using Methyl Aminolevulinate Hydrochloride ingredient
Treatment:
Metvixia is used for treating actinic keratoses using photodynamic therapy.
Dosage:
Metvixia is available in cream form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 16.8% BASE | CREAM | Discontinued | TOPICAL |